An Open Label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of a Single Dose Infusion of VABOMERE (Meropenem-Vaborbactam) in Pediatric Subjects From Birth to Less Than 18 Years of Age With Serious Bacterial Infections
Latest Information Update: 04 Mar 2025
At a glance
- Drugs Meropenem/vaborbactam (Primary)
- Indications Bacterial infections
- Focus Adverse reactions; Pharmacokinetics
- Acronyms TANGOKIDS
- Sponsors Melinta Therapeutics; Rempex Pharmaceuticals
Most Recent Events
- 28 Feb 2025 Planned primary completion date changed from 1 Dec 2024 to 1 Jun 2025.
- 26 Sep 2023 Planned End Date changed from 1 Dec 2023 to 1 Jun 2025.
- 26 Sep 2023 Planned primary completion date changed from 1 May 2023 to 1 Dec 2024.